Boston, MA 09/26/2014 (wallstreetpr) – According to reports, Signal Genetics Inc (NASDAQ:SGNL) and the University of Arkansas have decided to extend exclusive laboratory service agreements. SGNL is a commercial molecular diagnostic company with the prime focus of providing innovative and modern era diagnostic services to various hospitals and healthcare centers. With the help of its diagnostic services, a lot of physicians can gain quality knowledge and make far better decisions than they normally do, in regard with their patients suffering from cancer. The company has a proven track record and a lot of appreciations in this field.
Insights of the extended laboratory agreements:
Under the terms of agreements, the company will continue to offer gene array clinical genetic testing services till September 19, 2017. Both the parties found each other suitable to fulfill each other’s demand; hence, they have renewed the agreement which was signed earlier on March 11, 2011. While talking to reporters, Sam Riccitelli, President and CEO of Signal Genetics Inc (NASDAQ:SGNL) told that UAMS was one of the finest research centers of the world for the treatment of multiple myeloma. He further added that he and the entire management were delighted to extend this longstanding laboratory services arrangement for another three years. He said that the extension in the agreement was the result of Signal Genetics Inc (NASDAQ:SGNL)’s continual efforts for offering top-notched services in order to make physicians better informed.
His announcement earned a good praise in the market, both in terms of equity enhancement and brand recognition. Nobody else than Riccitelli was available to talk to reporters. Although they tried a lot, but they couldn’t reach anyone from the University of Arkansas to know more about this fact. Signal Genetics Inc (NASDAQ:SGNL) was found in 2010, and within four years of time, the company has achieved an untouchable milestone. The management of SGNL gives assurance about the future good performance.
